GEP20135805B - 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS - Google Patents

1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS

Info

Publication number
GEP20135805B
GEP20135805B GEAP200912221A GEAP2009012221A GEP20135805B GE P20135805 B GEP20135805 B GE P20135805B GE AP200912221 A GEAP200912221 A GE AP200912221A GE AP2009012221 A GEAP2009012221 A GE AP2009012221A GE P20135805 B GEP20135805 B GE P20135805B
Authority
GE
Georgia
Prior art keywords
piperazin
hydroxytryptamine
benzimidazoles
arylsulfonyl
ligands
Prior art date
Application number
GEAP200912221A
Other languages
English (en)
Inventor
Simon N Haydar
Patrick M Andrae
Albert J Robichaud
Heedong Yun
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20135805(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of GEP20135805B publication Critical patent/GEP20135805B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GEAP200912221A 2008-11-11 2009-11-10 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS GEP20135805B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
GEP20135805B true GEP20135805B (en) 2013-04-10

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP200912221A GEP20135805B (en) 2008-11-11 2009-11-10 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS

Country Status (41)

Country Link
US (1) US8063053B2 (en:Method)
EP (1) EP2285784B1 (en:Method)
JP (1) JP5087171B2 (en:Method)
KR (1) KR101323417B1 (en:Method)
CN (1) CN102209713B (en:Method)
AP (1) AP2814A (en:Method)
AR (1) AR074325A1 (en:Method)
AU (1) AU2009314221B2 (en:Method)
BR (1) BRPI0920682A2 (en:Method)
CA (1) CA2740262C (en:Method)
CL (1) CL2011001050A1 (en:Method)
CO (1) CO6440548A2 (en:Method)
CR (1) CR20110247A (en:Method)
CU (1) CU24020B1 (en:Method)
CY (1) CY1113025T1 (en:Method)
DK (1) DK2285784T3 (en:Method)
DO (1) DOP2011000130A (en:Method)
EA (1) EA018369B1 (en:Method)
EC (1) ECSP11011045A (en:Method)
ES (1) ES2389694T3 (en:Method)
GE (1) GEP20135805B (en:Method)
HR (1) HRP20120561T1 (en:Method)
IL (1) IL212213A0 (en:Method)
MA (1) MA32788B1 (en:Method)
ME (1) ME01129B (en:Method)
MX (1) MX2011004996A (en:Method)
MY (1) MY156324A (en:Method)
NI (1) NI201100093A (en:Method)
NZ (1) NZ592563A (en:Method)
PE (1) PE20120026A1 (en:Method)
PL (1) PL2285784T3 (en:Method)
PT (1) PT2285784E (en:Method)
RS (1) RS52381B (en:Method)
SA (1) SA109300673B1 (en:Method)
SI (1) SI2285784T1 (en:Method)
SV (1) SV2011003902A (en:Method)
TN (1) TN2011000203A1 (en:Method)
TW (1) TWI481605B (en:Method)
UA (1) UA100192C2 (en:Method)
WO (1) WO2010056644A1 (en:Method)
ZA (1) ZA201103283B (en:Method)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4958785B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
CA2580844A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
TW200626148A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
BRPI0515489A (pt) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
WO2021021951A1 (en) 2019-07-29 2021-02-04 Vanderbilt University Wdr5-myc inhibitors
IL297448A (en) * 2020-04-22 2022-12-01 Recurium Ip Holdings Llc Preparation of an selective estrogen receptor degrader

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0773942A1 (en) 1994-07-26 1997-05-21 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
JP2002511097A (ja) 1997-07-11 2002-04-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ▲下６▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
DK0930302T3 (da) 1998-01-16 2003-07-21 Hoffmann La Roche Benzosulfonderivater
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
JP4346243B2 (ja) 1998-08-10 2009-10-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロトン・ポンプ・インヒビターのプロドラッグ
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
BR0114552A (pt) 2000-10-20 2003-07-01 Biovitrum Ab N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia
SE0003810D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Novel compounds their use and preparations
CN1222511C (zh) * 2000-11-02 2005-10-12 惠氏公司 作为5－羟色胺－6配体的1－芳基－或1－烷基磺酰基－杂环基吲哚
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
BR0210411A (pt) * 2001-06-15 2004-08-17 Hoffmann La Roche Derivados 4-piperazinilindol com afinidade para o receptor 5-ht6
WO2003026665A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
JP4768265B2 (ja) 2002-10-15 2011-09-07 シンタ ファーマシューティカルズ コーポレーション 新規化合物
TWI380816B (zh) 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
BRPI0512674A (pt) 2004-07-28 2007-09-25 Irm Llc compostos e composições como moduladores de receptores nucleares de hormÈnio esteróide
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Also Published As

Publication number Publication date
CL2011001050A1 (es) 2011-08-19
EA018369B1 (ru) 2013-07-30
TWI481605B (zh) 2015-04-21
SI2285784T1 (sl) 2012-08-31
US20100120779A1 (en) 2010-05-13
CR20110247A (es) 2011-06-24
CO6440548A2 (es) 2012-05-15
HRP20120561T1 (hr) 2012-07-31
MY156324A (en) 2016-02-15
HK1158647A1 (en) 2012-07-20
KR20110075013A (ko) 2011-07-05
CA2740262C (en) 2013-05-28
EP2285784A1 (en) 2011-02-23
PT2285784E (pt) 2012-09-19
AR074325A1 (es) 2011-01-05
NI201100093A (es) 2011-10-31
PL2285784T3 (pl) 2012-12-31
DK2285784T3 (da) 2012-07-23
TN2011000203A1 (fr) 2012-12-17
CN102209713B (zh) 2014-07-02
ES2389694T3 (es) 2012-10-30
CY1113025T1 (el) 2016-04-13
CU24020B1 (es) 2014-07-30
IL212213A0 (en) 2011-06-30
SA109300673B1 (ar) 2013-05-25
AP2814A (en) 2013-12-31
ZA201103283B (en) 2012-01-25
JP5087171B2 (ja) 2012-11-28
AP2011005664A0 (en) 2011-04-30
RS52381B (en) 2012-12-31
JP2012508275A (ja) 2012-04-05
AU2009314221B2 (en) 2012-08-30
WO2010056644A1 (en) 2010-05-20
UA100192C2 (en) 2012-11-26
CN102209713A (zh) 2011-10-05
TW201022247A (en) 2010-06-16
NZ592563A (en) 2012-10-26
ME01129B (me) 2013-03-20
AU2009314221A1 (en) 2010-05-20
KR101323417B1 (ko) 2013-10-29
CU20110101A7 (es) 2012-01-31
WO2010056644A8 (en) 2010-11-18
MA32788B1 (fr) 2011-11-01
CA2740262A1 (en) 2010-05-20
SV2011003902A (es) 2011-07-05
DOP2011000130A (es) 2017-04-30
PE20120026A1 (es) 2012-02-12
MX2011004996A (es) 2011-05-25
EA201100696A1 (ru) 2011-10-31
BRPI0920682A2 (pt) 2016-09-27
EP2285784B1 (en) 2012-07-04
US8063053B2 (en) 2011-11-22
ECSP11011045A (es) 2011-06-30

Similar Documents

Publication Publication Date Title
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
GEP20146082B (en) Compositions and methods of wnt signaling modulators
MY154898A (en) P70 s6 kinase inhibitors
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
MY148634A (en) Pyridazinone derivatives
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
ZA200906264B (en) Aminopyrimidines useful as inhibitors of protein kinases
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
MY162157A (en) Substituted indole mcl-1 inhibitors
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
MY161461A (en) Akt and p70 s6 kinase inhibitors
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
TW200738651A (en) Cyclohexyl sulfonamide derivatives
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
TW200616953A (en) Indole, indazole or indoline derivatives
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
UA99787C2 (en) Lactams as beta secretase inhibitors